Can Fite Biopharma Ltd (AMEX:CANF)‘s stock had its “buy” rating restated by analysts at Roth Capital in a research report issued to clients and investors on Wednesday, reports.

Separately, Rodman & Renshaw started coverage on shares of Can Fite Biopharma in a research note on Monday, August 29th. They set a “buy” rating and a $6.00 target price for the company.

Can Fite Biopharma (AMEX:CANF) traded down 0.612% on Wednesday, hitting $2.435. The stock had a trading volume of 67,215 shares. The firm’s market cap is $34.64 million. Can Fite Biopharma has a 52-week low of $1.85 and a 52-week high of $4.05. The company has a 50-day moving average price of $2.50 and a 200 day moving average price of $2.57.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Stock Target Prices

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with's FREE daily email newsletter.